New Risk • Jun 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). New Risk • Jun 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩19b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩137.5b market cap, or US$91.1m). New Risk • May 28
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩144.7b (US$96.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (₩144.7b market cap, or US$96.2m). New Risk • Apr 10
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 22% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (22% increase in shares outstanding). New Risk • Apr 07
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩147.7b (US$98.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (₩147.7b market cap, or US$98.5m). Announcement • Mar 17
Vivozon Pharmaceutical Co., Ltd., Annual General Meeting, Mar 31, 2026 Vivozon Pharmaceutical Co., Ltd., Annual General Meeting, Mar 31, 2026, at 13:00 Tokyo Standard Time. Location: conference room, 135-21, madangbawi-ro, paltan-myeon, gyeonggi-do, hwaseong South Korea New Risk • Mar 03
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Announcement • Feb 25
Vivozon Pharmaceutical Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 32.534975 billion. Vivozon Pharmaceutical Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 32.534975 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 10,615,000
Price\Range: KRW 3065
Discount Per Security: KRW 61.3
Transaction Features: Rights Offering Reported Earnings • Nov 12
Third quarter 2025 earnings released: ₩234 loss per share (vs ₩3.06 profit in 3Q 2024) Third quarter 2025 results: ₩234 loss per share (down from ₩3.06 profit in 3Q 2024). Revenue: ₩6.76b (down 71% from 3Q 2024). Net loss: ₩11.6b (down ₩11.7b from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Announcement • Oct 14
Vivozon Pharmaceutical Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 49.99665 billion. Vivozon Pharmaceutical Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 49.99665 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 10,615,000
Price\Range: KRW 4710
Discount Per Security: KRW 94.2
Transaction Features: Rights Offering New Risk • Sep 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩6.4b free cash flow). Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change). New Risk • Aug 30
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company. New Risk • Aug 29
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩6.4b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. This is currently the only risk that has been identified for the company. Announcement • Mar 15
Vivozon Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2025 Vivozon Pharmaceutical Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 135-21, madangbawi-ro, paltan-myeon, gyeonggi-do, hwaseong South Korea Announcement • Feb 18
Vivozon Pharmaceutical Obtains Mfds Approval for Unafra Inj.: A Breakthrough Non-Opioid Analgesic On February 17, VIVOZON Pharmaceutical announced that its non-opioid analgesic, UNAFRA Inj., was approved on December 12, 2024. (Active ingredient: Opiranserin HCl) has received approval from the Ministry of Food and Drug Safety (MFDS). With this milestone, UNAFRA inj. has become the 38th innovative drug in Korea. UNAFRA Inj. discovered by using the company's proprietary multi-target drug development platform, is the world's first non-opioid, non-NSAIDS analgesic. It induces analgesic effect by simultaneously inhibiting Glycine Transporter Type 2 (GlyT2) and Serotonin Receptor 2a (5HT2a), thereby blocking pain signals and transmission synergistically across both the central and peripheral nervous systems. Previously, VIVOZON pharmaceutical confirmed the safety and tolerance of the drug and secured statistical significance for efficacy in a domestic Phase 3 clinical trial and applied for new drug application (NDA) from MFDS in November 2023. The efficacy of the drug was confirmed through the primary endpoint Sum of Pain Intensity Difference over 12 Hours (SPID 12), and secondary endpoints including number of Patient-Controlled Analgesia (PCA) requests and opioid consumption over 12 Hours. This approval marks a breakthrough in the treatment landscape for moderate to severe pain, addressing the high unmet medical needs in a market that previously lacked alternatives to opioid analgesics. UNAFRA InJ. has beenailed as a game changer by the medical community, showing rapid pain relief with fewer side effects and zero risk of addiction compared to existing opioids with severe addiction. The company emphasized that UNAFRA Inj stands apart from earlier domestically developed drugs, which were primarily "Best-in-Class" or "Me- too" drugs mimicking existing treatments. In contrast, UNAFRA In J. is Korea's first "First-in-Class" innovative new drug, demonstrating significant advancements in drug development complexity and originality. New Risk • Nov 28
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Shareholders have been diluted in the past year (2.4% increase in shares outstanding). New Risk • Nov 08
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. New Risk • Aug 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.1% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change). Reported Earnings • May 19
First quarter 2024 earnings released: ₩39.72 loss per share (vs ₩48.87 loss in 1Q 2023) First quarter 2024 results: ₩39.72 loss per share (improved from ₩48.87 loss in 1Q 2023). Revenue: ₩19.9b (up 45% from 1Q 2023). Net loss: ₩933.3m (loss narrowed 20% from 1Q 2023). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings. New Risk • Apr 19
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩137.8b (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩137.8b market cap, or US$99.8m). Board Change • Nov 10
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Announcement • Sep 21
Vivozon Pharmaceutical Co., Ltd. (KOSDAQ:A082800) announces an Equity Buyback for KRW 5 million worth of its shares. Vivozon Pharmaceutical Co., Ltd. (KOSDAQ:A082800) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5 million worth of its shares. The purpose of the program is Free contribution to the Employee Stock Ownership Association to pay bonuses to executives and employees. The program will continue through September 19, 2024. As of September 18, 2023, the company had 0 and 0 treasury stock holdings in acquisition within the scope of dividends and other acquisition co., ltd., respectively. Reported Earnings • Mar 31
Full year 2022 earnings released: ₩177 loss per share (vs ₩426 loss in FY 2021) Full year 2022 results: ₩177 loss per share (improved from ₩426 loss in FY 2021). Revenue: ₩59.1b (up 2.6% from FY 2021). Net loss: ₩38.5b (loss narrowed 45% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Announcement • Jan 10
Vivozon Pharmaceutical Co., Ltd. announced that it expects to receive KRW 2.000000072 billion in funding Vivozon Pharmaceutical Co., Ltd. announced a private placement that it will issue 2,915,452 common shares at an issue price of KRW 686 for the total gross proceeds of KRW 2,000,000,072 on January 9, 2023. The company will issue shares through third-party allotment. The transaction has been approved by the board of the directors. The transaction is expected to close on February 28, 2023. Announcement • Dec 21
Vivozon Pharmaceutical Co., Ltd. announced that it has received KRW 6 billion in funding On December 20, 2022, Vivozon Pharmaceutical Co., Ltd closed the transaction. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Announcement • Apr 07
Vivozon Healthcare, Inc. announced that it has received KRW 58.171164251 billion in funding from Vaultea, Inc. and other investors On April 5, 2022, Vivozon Healthcare, Inc. closed the transaction. Announcement • May 11
Vivozon Healthcare, Inc. announced that it expects to receive KRW 10 billion in funding from Korea Fixed Income Investment Advisory Co., Ltd. Vivozon Healthcare, Inc. (KOSDAQ:A082800) announced that it will issue series 19 non-guaranteed private equity convertible bonds for gross proceeds of KRW 10,000,000,000 to existing investor Korea Fixed Income Investment Advisory Co., Ltd. on May 10, 2021. The bonds will have surface interest of 2% per annum payable quarterly and interest to maturity of 4%. The bonds will be issued at par and matures on July 14, 2024. The bonds are convertible into 6,535,947 shares representing 4.09% stake at a fixed conversion price of KRW 1,530 per share from July 14, 2022 to June 14, 2024. The bonds are redeemable from January 14, 2023 to April 14, 2024 at premium. The expected payment date is July 14, 2021. The transaction is approved by the board of directors of the company. Reported Earnings • Mar 26
Full year 2020 earnings released: ₩334 loss per share (vs ₩213 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: ₩43.6b (down 3.0% from FY 2019). Net loss: ₩43.8b (loss widened 102% from FY 2019). Is New 90 Day High Low • Feb 24
New 90-day low: ₩1,780 The company is down 21% from its price of ₩2,255 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Semiconductor industry, which is up 34% over the same period. Is New 90 Day High Low • Dec 28
New 90-day low: ₩1,955 The company is down 15% from its price of ₩2,310 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Semiconductor industry, which is up 30% over the same period. Is New 90 Day High Low • Sep 24
New 90-day high: ₩2,435 The company is up 32% from its price of ₩1,850 on 26 June 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Semiconductor industry, which is up 5.0% over the same period. Announcement • Sep 24
Lumimicro Co., Ltd (KOSDAQ:A082800) agreed to acquire 85.78% stake in Inist Bio Co.,Ltd. from Inistpharm Co.,Ltd, Kim, Kook-Hyun, Park, Ji-seop and others for KRW 60.9 billion. Lumimicro Co., Ltd (KOSDAQ:A082800) agreed to acquire 85.78% stake in Inist Bio Co.,Ltd. from Inistpharm Co.,Ltd, Kim, Kook-Hyun, Park, Ji-seop and others for KRW 60.9 billion on September 23, 2020. Lumimicro Co., Ltd will acquire 2.16 million shares of Inist Bio Co.,Ltd. The consideration will be paid in cash with KRW 18.27 billion paid on September 23, 2020 and KRW 42.63 billion on September 29, 2020. The transaction will be funded from cash held in hand. The transaction is expected to close on September 29, 2020. 
